Biotech

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔8/23/2019 8:15:53 AM

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the Monsoon Communications Twilight Investor Briefing, yesterday evening, in Melbourne.

Read Full Article

Ellis Martin Report with Neurotrope's (NASDAQ:NTRP) Dr. Daniel Alkon: Reversing Alzheimer's Disease.

🕔8/19/2019 12:39:05 PM

Join Ellis Martin for an exclusive conversation pertinent to the world of the disruptive disease called Alzheimers. Can this dreadful malady be reversed offering hope to victims and their families? Can neurons in the brain be regrown?

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Live Investor Briefing

🕔8/16/2019 9:06:24 AM

Anatara Lifesciences Ltd's (ASX:ANR) CEO, Steve Lydeamore will be presenting to investors at a Monsoon Communications Twilight Investor Briefing event in Melbourne next week. Investors interested in attending this presentation are invited to reach out.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Animal Health Assets Update

🕔8/5/2019 9:22:28 AM

Anatara Lifesciences (ASX:ANR) provides an update on the strategic evaluation of Detach(R), its non-antibiotic animal health asset which aids in the control of diarrhoeal disease in piglets (known as scour), with potential application in other livestock animals, aquaculture and companion animals.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔7/29/2019 8:16:02 AM

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the 15th Bioshares Biotech Summit, held in Queenstown, New Zealand, 26th to 27th July 2019.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Appendix 4C - Quarterly

🕔7/25/2019 8:27:52 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th June 2019. The Company's cash plus term deposits at the end of the quarter stood at $5.4m. On 30th June 2019, the Company had cash at bank of $1,360,086 and $4,050,000 in term deposits. Expenditure during the quarter was in line with forecast.

Read Full Article

Anatara Life Sciences Ltd (ASX:ANR) CEO Steve Lydeamore To Present at Bioshares

🕔7/24/2019 9:36:15 AM

Anatara's CEO, Steve Lydeamore will be presenting to investors during the Bioshares Biotech Summit this Friday, and at a Monsoon Communications Twilight Investor Briefing event in Melbourne during August.

Read Full Article